Subscription Model Proposed to Fix Broken Antibiotic Market

The global healthcare community is currently grappling with a market failure of existential proportions. As antimicrobial resistance (AMR) continues to escalate, rendering once-routine infections potentially fatal, the pipeline for new antibiotics has effectively dried up. Experts in Australia and internationally are now sounding the alarm, advocating for a radical shift in how these drugs are funded. The proposed 'Netflix-style' subscription model is viewed as a critical intervention to fix the broken economics of drug development, where the traditional volume-based sales model actively discourages the creation of the very products the world needs most.

The fundamental issue lies in the paradox of antibiotic stewardship. Unlike a new oncology treatment or a chronic heart medication, where high volume and long-term use drive profit, a powerful new antibiotic is most valuable when it is not used. To prevent the development of resistance, clinicians must reserve the newest, most effective drugs for the most desperate cases. For a pharmaceutical company, this creates a massive financial deterrent: spending upwards of $1 billion on research and development for a product that health authorities will then tell doctors to prescribe as rarely as possible. This commercial misalignment has led to a mass exodus of major pharmaceutical players from the space, leaving the field to small biotechs that often face bankruptcy shortly after bringing a drug to market.

“

For a pharmaceutical company, this creates a massive financial deterrent: spending upwards of $1 billion on research and development for a product that health authorities will then tell doctors to prescribe as rarely as possible.

The proposed subscription model—often referred to as a 'pull incentive'—reimagines the relationship between governments and drug makers. Instead of paying per pill or per vial, a government or health system pays an annual fixed fee for guaranteed access to a portfolio of antibiotics. This provides manufacturers with a predictable, de-risked revenue stream regardless of how much of the drug is actually dispensed. It mirrors the subscription model used by streaming giants like Netflix: the consumer pays for the availability of the content, not for every minute watched. In a clinical setting, this removes the commercial pressure to over-market drugs, aligning the interests of the manufacturer with the public health goal of stewardship.

The United Kingdom has already provided a successful proof-of-concept for this strategy. In 2022, the National Health Service (NHS) launched a world-first pilot program, awarding contracts to companies for access to critical antimicrobials. The success of this pilot has sparked global interest, with the United States debating the PASTEUR Act, which would implement a similar incentive program. Australian experts are now urging their federal government to join this international movement, arguing that as a wealthy nation with a robust healthcare system, Australia has a moral and economic imperative to contribute to the global antibiotic insurance policy.

The implications of failing to act are stark. Without new antibiotics, the foundations of modern medicine—including chemotherapy, organ transplants, and routine surgeries—become significantly more dangerous. The economic impact is equally concerning; the World Bank estimates that AMR could result in a 3.8 percent decrease in global GDP by 2050. By shifting to a subscription-based procurement model, governments can effectively pre-pay for the security of having effective treatments available when the next superbug emerges. This transition represents a shift from a transactional model to a strategic partnership model, where the value of a drug is measured by its existence as a safeguard rather than its frequency of use.

Looking ahead, the challenge will be international coordination. Because the market for any single antibiotic is global, a subscription model in one small country may not be enough to move the needle for a multi-billion dollar R&D budget. Analysts expect to see a push for a G7-plus approach, where major economies harmonize their incentive structures to create a sustainable, multi-billion dollar global market for new antimicrobials. For investors and healthcare providers, this represents a fundamental change in the valuation of infectious disease assets, potentially revitalizing a sector that has been neglected for decades.